1. Home
  2. OSUR vs SABS Comparison

OSUR vs SABS Comparison

Compare OSUR & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OraSure Technologies Inc.

OSUR

OraSure Technologies Inc.

HOLD

Current Price

$4.00

Market Cap

295.7M

Sector

Health Care

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

N/A

Current Price

$3.75

Market Cap

342.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OSUR
SABS
Founded
2000
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
295.7M
342.1M
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
OSUR
SABS
Price
$4.00
$3.75
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$3.00
$10.75
AVG Volume (30 Days)
397.4K
480.5K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
78.53
EPS
N/A
N/A
Revenue
$167,064,000.00
N/A
Revenue This Year
$4.48
N/A
Revenue Next Year
$7.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.08
$1.85
52 Week High
$4.58
$5.15

Technical Indicators

Market Signals
Indicator
OSUR
SABS
Relative Strength Index (RSI) 49.05 52.00
Support Level $3.89 $3.68
Resistance Level $4.29 $4.09
Average True Range (ATR) 0.18 0.17
MACD -0.01 0.02
Stochastic Oscillator 57.27 64.52

Price Performance

Historical Comparison
OSUR
SABS

About OSUR OraSure Technologies Inc.

OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: